ESPR

Esperion Therapeutics Inc

ESPR, USA

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

https://www.esperion.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ESPR
stock
ESPR

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) The Manila Times

Read more →
ESPR
stock
ESPR

Esperion Grants Stock Options and RSUs to New Chief Commercial Officer and Employees Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$6.5025

Analyst Picks

Strong Buy

2

Buy

2

Hold

2

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-1.73

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

6.94 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-8.61 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-4.91 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 65.70% of the total shares of Esperion Therapeutics Inc

1.

BlackRock Inc

(7.2973%)

since

2025/06/30

2.

Vanguard Group Inc

(5.8113%)

since

2025/06/30

3.

Wasatch Advisors LP

(5.1285%)

since

2025/06/30

4.

Two Seas Capital LP

(4.9374%)

since

2025/06/30

5.

BB Biotech AG Ord

(4.932%)

since

2024/12/31

6.

Wasatch Ultra Growth

(3.482%)

since

2025/06/30

7.

Penderfund Capital Management Ltd

(3.3114%)

since

2025/06/30

8.

Pender Corporate Bond F

(3.1544%)

since

2025/05/31

9.

Vanguard Total Stock Mkt Idx Inv

(2.9988%)

since

2025/07/31

10.

Marshall Wace Asset Management Ltd

(2.6347%)

since

2025/06/30

11.

iShares Russell 2000 ETF

(2.402%)

since

2025/08/31

12.

Geode Capital Management, LLC

(2.2735%)

since

2025/06/30

13.

State Street Corp

(1.8642%)

since

2025/06/30

14.

Indaba Capital Management, LLC

(1.4879%)

since

2025/06/30

15.

Citadel Advisors Llc

(1.1552%)

since

2025/06/30

16.

Two Sigma Advisers, LLC

(1.0384%)

since

2025/06/30

17.

Fidelity Small Cap Index

(0.9871%)

since

2025/06/30

18.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9746%)

since

2025/07/31

19.

Two Sigma Investments LLC

(0.9066%)

since

2025/06/30

20.

Northern Trust Corp

(0.8849%)

since

2025/06/30

21.

UBS Group AG

(0.7624%)

since

2025/06/30

22.

Woodline Partners LP

(0.7458%)

since

2025/06/30

23.

Royal Bank of Canada

(0.5786%)

since

2025/06/30

24.

iShares Russell 2000 Value ETF

(0.578%)

since

2025/08/31

25.

Morgan Stanley - Brokerage Accounts

(0.5235%)

since

2025/06/30

26.

Vanguard Explorer Inv

(0.5013%)

since

2025/06/30

27.

Fidelity Extended Market Index

(0.4857%)

since

2025/07/31

28.

Vanguard Russell 2000 ETF

(0.4741%)

since

2025/07/31

29.

Susquehanna International Group, LLP

(0.4149%)

since

2025/06/30

30.

Bank of America Corp

(0.4148%)

since

2025/06/30

31.

Goldman Sachs Group Inc

(0.3962%)

since

2025/06/30

32.

State St Russell Sm Cap® Indx SL Cl I

(0.3179%)

since

2025/08/31

33.

iShares Russell 2000 Growth ETF

(0.2892%)

since

2025/08/31

34.

Schwab Small Cap Index

(0.2586%)

since

2025/07/31

35.

NT R2000 Index Fund - NL

(0.2396%)

since

2025/06/30

36.

Wasatch Long/Short Alpha Institutional

(0.2361%)

since

2025/06/30

37.

iShares Micro-Cap ETF

(0.224%)

since

2025/08/31

38.

Renaissance Global Small Cap

(0.2079%)

since

2025/05/31

39.

Wasatch Long Short Alpha Composite

(0.201%)

since

2025/03/31

40.

NT R2000 Index Fund - DC - NL - 3

(0.191%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.2937

Latest Release

Date

2025-09-30

EPS Actual

-0.16

EPS Estimate

0.02

EPS Difference

-0.18

Surprise Percent

-900%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.